PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding
NCT ID: NCT00562198
Last Updated: 2008-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
16 participants
INTERVENTIONAL
2008-01-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Investigational drug Stalevo 200
entacapone and carbidopa
Entacapone 200mg carbidopa 50mg
Sinemet 200mg/50mg
Sinemet 200mg/50mg once
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
entacapone and carbidopa
Entacapone 200mg carbidopa 50mg
Sinemet 200mg/50mg
Sinemet 200mg/50mg once
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Predictable wearing-off symptoms with a response to standard release levodopa/carbidopa (200/50 mg)during the levodopa challenge test lasting for a minimum of 1.5 h and a maximum of 4 h.
3. The magnitude of response (peak effect) in the levodopa challenge test is at least 30%. The magnitude of response is defined to be the difference between the baseline score and the lowest UPDRS III score during the levodopa challenge test.
4. Hoehn and Yahr stage of at least 2.0 performed during the "ON" state.
5. Treatment with at least 4 daily doses of levodopa/dopa decarboxylase inhibitor (DDCI) (± entacapone(Comtess® or Stalevo) with total daily levodopa dose in the range of 400-1200mg.
6. Unchanged levodopa/DDCI ± entacapone and other antiparkinsonian medication \[dopamine agonists,monoamine oxidase B (MAO-B) inhibitor, amantadine and/or anticholinergics with an approved dose\], if any, for at least 2 weeks prior to period I.
7. Written informed consent obtained.
8. Age of 45-80 years, inclusive.
Exclusion Criteria
2. Patients with any unpredictable "OFF"-periods.
3. Patients with moderate to severe treatment-related peak-dose dyskinesia likely to affect the quality of brain magnetic resonance image (MRI) or positron emission tomography (PET) imaging.
4. Failure to adequately respond to the levodopa (levodopa/carbidopa 200/50 mg) challenge test with the duration of response lasting less than 1.5 h or more than 4 h.
5. Presence of a basal ganglia lesion in the MRI image or any other factor(s) that would make MRI or PET imaging likely to be unsatisfactory.
6. Presence of any ferromagnetic objects that would make brain MRI imaging contraindicated.
7. Patients with a history of laboratory abnormality consistent with, or clinically significant cardiovascular,pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness, which may influence the outcome of the study including the interpretation and usage of MRI and PET images for the study purposes.
8. History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis, malignant melanoma, narrow-angle glaucoma or pheochromocytoma.
9. Severe hepatic impairment.
10. Any abnormal electrocardiogram (ECG) finding with clinical relevance.
11. Female patients of childbearing potential (menstruating or less than 2 years post-menopausal) if they are not using adequate contraception during the study (defined as hormonal contraception, intrauterine device or surgical sterilization) or female patients who are pregnant or lactating.
12. Treatment with cabergoline.
13. Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors.
14. Concomitant treatment with any drugs with antidopaminergic action (e.g. with D2 receptor blocking properties) less than two weeks or within five times the elimination half-life of a given drug prior to the first study drug administration. As an exception, the use of domperidone is allowed.
15. Current, regular use of any iron preparation that cannot be interrupted for the duration of the study
16. Patients who are likely to need a rescue dose of levodopa after the withdrawal from their own levodopa/DDCI ± entacapone medication prior to PET imaging.
17. Known hypersensitivity to active study drug substances or to any of the excipients.
18. Participation in other drug studies within 30 days prior to study entry.
19. Blood donation or loss of significant amount of blood within 60 days prior to the screening.
20. Any other condition that in the opinion of the investigator could create a hazard to the subject safety,endanger the study procedures or interfere with the interpretation of study results.
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orion Corporation, Orion Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Orion Pharma
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juha Rinne, Dr
Role: PRINCIPAL_INVESTIGATOR
Turku PET Centre, Turku, Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Hospital, Department of Neurology
Helsinki, , Finland
Oulu University Hospital, Department of Neurology
Oulu, , Finland
Porin Lääkäritalo
Pori, , Finland
FinnMedi Tutkimus Oy
Tampere, , Finland
CRST
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2939121
Identifier Type: -
Identifier Source: org_study_id